Alpha Tau Medical Ltd（DRTS）資訊與事件DRTSAlpha Tau Medical Ltd

Alpha Tau Completes Patient Enrollment in IMPACT Study

Alpha Tau announced the completion of patient enrollment in its IMPACT study - a multicenter pilot study evaluating intratumoral Alpha DaRT in combination with first-line chemotherapy for patients with newly diagnosed, unresectable locally advanced or metastatic pancreatic adenocarcinoma. A total of 48 patients have been enrolled.

Alpha Tau Achieves Major Progress in Q2 2026

"The second quarter of 2026 was without question the busiest and most consequential period in Alpha Tau's history, and the momentum has only continued to accelerate since," said Alpha Tau CEO Uzi Sofer. "In the space of a few weeks we reported groundbreaking interim results in recurrent glioblastoma, completed enrollment in our first U.S. pivotal trial, presented compelling new pancreatic cancer survival data at both Digestive Disease Week and the ASCO Annual Meeting, and announced our first major U.S. commercial partnership. This Company continues to transform itself completely, from a single-asset clinical story into a broad, multi-indication platform with a partnered commercial pathway and a rapidly expanding global clinical footprint."

Alpha Tau Reports Clinical Study Results for Alpha DaRT

Alpha Tau announced results from a clinical study evaluating Alpha DaRT in combination with pembrolizumab in elderly patients with locally advanced and metastatic head and neck squamous cell carcinoma, or HNSCC, in which the combination produced a 100% objective response rate and a median overall survival of 18.2 months among evaluable patients. The results are being presented in a podium presentation at the American Head and Neck Society, or AHNS, 12th International Conference on Head and Neck Cancer, held July 18-22, in Boston, Massachusetts. Among evaluable patients, treatment with Alpha DaRT plus pembrolizumab produced an objective response rate of 100%, including four complete responses and five partial responses, for a complete response rate of 44%. By comparison, pembrolizumab monotherapy in the PD-L1 CPS greater than or equal to1 population of KEYNOTE-048 produced an objective response rate of approximately 19%. Median overall survival was 18.2 months, and median progression-free survival was 5.4 months, with four patients remaining alive at the time of this analysis. By comparison, pembrolizumab monotherapy in a similar population in the KEYNOTE-048 trial achieved a median overall survival of 12.3 months and a median progression-free survival of approximately 3.2 months. No Alpha DaRT-related serious adverse events were observed. Only two Alpha DaRT-related adverse events were reported across the treated cohort, both Grade 1 in severity.